Curve Therapeutics Co-Founder Professor Ali Tavassoli Honored with Royal Society of Chemistry's Interdisciplinary Prize

Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli Recognized with RSC Prize

In a significant achievement for the biotechnology field, Professor Ali Tavassoli, the Co-Founder and Chief Scientific Officer of Curve Therapeutics, was awarded the Interdisciplinary Prize by the Royal Society of Chemistry. This prestigious award celebrates his outstanding contributions to research, focusing particularly on high-throughput intracellular production and screening of cyclic peptide libraries. Professor Tavassoli's work plays a pivotal role in addressing crucial intracellular disease targets, paving the way for innovative therapeutic solutions.

Professor Tavassoli is also renowned for his role as a Professor of Chemical Biology at the University of Southampton, where his research has significantly advanced our understanding of protein-protein interactions. His revolutionary approach utilizes cyclic peptides to identify inhibitors that can potentially transform treatment methodologies for various diseases.

Expressing his gratitude upon receiving the award, Professor Tavassoli stated, "I am deeply honored to receive this award. However, scientific progress is never a solo endeavor, and I'm incredibly fortunate to work with an exceptional team, whose dedication, creativity and collaboration have been central to advancing our shared vision for intracellular screening of cyclic peptide libraries. Today's award therefore reflects the collective efforts of many people."

The award highlights the incredible potential of Curve Therapeutics’ proprietary Microcycle® technology, which is aimed at unlocking the therapeutic possibilities of intracellular targets. As explained by Simon Kerry, the CEO of Curve Therapeutics, the application of their unique Microcycle discovery platform allows for the identification of biologically active molecules derived from libraries of Microcycles, particularly within live mammalian cells. Such advancements mark a significant leap towards more effective treatment options in fields such as oncology and neurology, particularly through innovative drug development strategies.

Professor Tavassoli's work contributes to Curve’s goal of building a strong pipeline of cyclic peptide and small molecule drugs that address high-priority targets in cancer, immunology, and inflammation. This reflects a broader mission to tackle pressing health challenges through advanced scientific research and methodical exploration in biotechnology.

The Royal Society of Chemistry has a long-standing tradition of recognizing excellence in chemical sciences, awarding prizes for over 150 years. Notably, many previous awardees have gained further recognition, including Nobel Prizes for their groundbreaking work. Professor Tavassoli now joins this distinguished lineup of laureates, which underscores the importance and impact of his research.

About Curve Therapeutics:
Curve Therapeutics operates at the frontier of biomedical innovation, specializing in a novel gene-encoded Microcycle® discovery platform. This approach ensures the robust development of functional cyclic peptides and small molecules through high-throughput functional screening applied in relevant biological settings, significantly enhancing the therapeutic landscape for intracellular targets. With backing from prominent investors such as Advent Life Sciences and Pfizer Ventures, Curve Therapeutics is poised for a significant impact in the biopharmaceutical industry.

As Curve continues to innovate and expand its research capabilities, the contributions of leaders like Professor Tavassoli will undoubtedly shape the future of biotechnology, driving forward scientific discoveries that hold transformative potential for health care and treatment methodologies worldwide.